Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors

To identify peptides with high affinity and specificity against human epidermal growth factor receptor 2 (HER2), a series of peptides were designed based on the structure of HER2 and its Z(HER2:342) affibody. By using a combination protocol of molecular dynamics modeling, MM/GBSA binding free energy calculations, and binding free energy decomposition analysis, two novel peptides with 27 residues, pep27 and pep27-24M, were successfully obtained. Immunocytochemistry and flow cytometry analysis verified that both peptides can specifically bind to the extracellular domain of HER2 protein at cellular level. The Surface Plasmon Resonance imaging (SPRi) analysis showed that dissociation constants (KD) of these two peptides were around 300 nmol/L. Furthermore, fluorescence imaging of peptides against nude mice xenografted with SKBR3 cells indicated that both peptides have strong affinity and high specificity to HER2 positive tumors.

[1]  Zhiyuan Hu,et al.  Label-free detection microarray for novel peptide ligands screening base on MS-SPRi combination. , 2015, Talanta.

[2]  F. Zoulim,et al.  Protein-Peptide Arrays for Detection of Specific Anti-Hepatitis D Virus (HDV) Genotype 1, 6, and 8 Antibodies among HDV-Infected Patients by Surface Plasmon Resonance Imaging , 2015, Journal of Clinical Microbiology.

[3]  L. Hood,et al.  Rapid screening of peptide probes through in situ single-bead sequencing microarray. , 2014, Analytical chemistry.

[4]  Tingjun Hou,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. , 2014, Physical chemistry chemical physics : PCCP.

[5]  J. Sridhar,et al.  Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer , 2014, Molecules.

[6]  Zhiyuan Hu,et al.  Label-Free Quantitative Detection of Tumor-Derived Exosomes through Surface Plasmon Resonance Imaging , 2014, Analytical chemistry.

[7]  E. Gorodkiewicz,et al.  Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging , 2014, Oncology letters.

[8]  S. Tolaney.  New HER2-Positive Targeting Agents in Clinical Practice , 2014, Current Oncology Reports.

[9]  S. Nam,et al.  Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice , 2013, Journal of veterinary science.

[10]  Wei Cui,et al.  Unraveling the Allosteric Inhibition Mechanism of PTP1B by Free Energy Calculation Based on Umbrella Sampling , 2013, J. Chem. Inf. Model..

[11]  Wei Cui,et al.  Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases , 2012, Journal of Computer-Aided Molecular Design.

[12]  H. Gohlke,et al.  Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method , 2012, Molecular informatics.

[13]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[14]  L. Abrahmsén,et al.  Structural basis for high-affinity HER2 receptor binding by an engineered protein , 2010, Proceedings of the National Academy of Sciences.

[15]  V. Prasad,et al.  Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules , 2010, Journal of Nuclear Medicine.

[16]  M. Hung,et al.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines , 2010, Breast cancer : basic and clinical research.

[17]  Wei Zhang,et al.  Characterization of Domain-Peptide Interaction Interface , 2009, Molecular & Cellular Proteomics.

[18]  J. Carlsson,et al.  Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. , 2008, Biochemical and biophysical research communications.

[19]  V. Chernomordik,et al.  Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging , 2008, Clinical Cancer Research.

[20]  D. Case,et al.  Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. , 2008, Journal of molecular biology.

[21]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[22]  Vladimir Tolmachev,et al.  Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.

[23]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[24]  J. Mackey,et al.  Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[26]  Xiaojie Xu,et al.  Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models , 2006 .

[27]  J. Carlsson,et al.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.

[28]  G. Adams,et al.  Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[30]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[31]  G. Adams,et al.  In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. , 2005, Cancer biotherapy & radiopharmaceuticals.

[32]  G. Adams,et al.  Selection and characterization of HER2/neu-binding affibody ligands. , 2004, Protein engineering, design & selection : PEDS.

[33]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[34]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[35]  James M Aramini,et al.  Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data , 2004, Protein science : a publication of the Protein Society.

[36]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[37]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[38]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[39]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[40]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[41]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[42]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[43]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[44]  Jörg Weiser,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..

[45]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[47]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[49]  M. Uhlén,et al.  A synthetic IgG-binding domain based on staphylococcal protein A. , 1987, Protein engineering.

[50]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[51]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[52]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[53]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[54]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[55]  D. Case,et al.  Theory and applications of the generalized born solvation model in macromolecular simulations , 2000, Biopolymers.